Clinical Trial Update: CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating CD19 and CD22 bispecific CAR T cells for relapsed/refractory B-cell hematologic tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoblastic Leukemia
• B-cell Lymphoma

Drugs mentioned

• CD19/CD22 bispecific CAR T cells (CD19/CD22 bispecific chimeric antigen receptor T cells)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: B-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1, Phase 2 | Status: RECRUITING